Cleared Traditional

K914507 - DOUBLE ANTIBODY CANNABIONOIDS/QUAIL DET...

K914507 is the FDA 510(k) clearance for DOUBLE ANTIBODY CANNABIONOIDS/QUAIL DET... by Diagnostic Products Corp.. It is a Class 2 Toxicology device (product code LAT) cleared through the Traditional 510(k) pathway after a 70-day FDA review.

K914507 · Diagnostic Products Corp. · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 1991
Decision
70d
Days
Class 2
Risk

K914507 is an FDA 510(k) clearance for the DOUBLE ANTIBODY CANNABIONOIDS/QUAIL DETER IN URINE. Classified as Radioimmunoassay, Cannabinoid(s) (product code LAT), Class II - Special Controls.

Submitted by Diagnostic Products Corp. (Los Angeles, US). The FDA issued a Cleared decision on December 18, 1991 after a review of 70 days - a notably fast clearance cycle.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3870 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Diagnostic Products Corp. devices

Submission Details

510(k) Number K914507 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 09, 1991
Decision Date December 18, 1991
Days to Decision 70 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary Statement
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
17d faster than avg
Panel avg: 87d · This submission: 70d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code LAT Radioimmunoassay, Cannabinoid(s)
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3870
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - LAT Radioimmunoassay, Cannabinoid(s)

All 13
Devices cleared under the same product code (LAT) and FDA review panel - the closest regulatory comparables to K914507.
ABISCREEN ONLINE FOR CANNABINOIDS - ES 50/100
K961620 · Roche Diagnostic Systems, Inc. · Jun 1996
ABUSCREEN(R) ONLINE(TM) FOR THC(50/100)(100TEST KT
K913414 · Roche Diagnostic Systems, Inc. · Sep 1991
URINE THC DIRECT RIA KIT (I-125)
K913865 · Immunalysis Corporation · Sep 1991
ABUSCREEN ONLINE FOR THC (50 AND 100)
K912574 · Roche Diagnostic Systems, Inc. · Aug 1991
ABUSCREEN ONLINE TM FOR THC
K904996 · Roche Diagnostic Systems, Inc. · Jan 1991
ORAL THC-CANNABINOIDS DIRECT RIA KIT
K843534 · Immunalysis Corporation · Oct 1984